Liontrust Investment Partners LLP Has $124.53 Million Stock Position in Masimo Corporation $MASI

Key Points

• Liontrust Investment Partners LLP reduced its holdings in Masimo Corporation by 5.7% in the first quarter, holding 747,498 shares worth approximately $124.53 million, which is 1.9% of its portfolio.
• Masimo reported positive earnings for the last quarter, with earnings per share of $1.33, surpassing analysts' expectations, and a revenue increase of 7.7% year-over-year.
• Despite institutional investors owning 85.96% of the stock, several brokerages have adjusted their target prices for Masimo, with Piper Sandler increasing it from $200.00 to $210.00.

Liontrust Investment Partners LLP decreased its stake in Masimo Corporation (NASDAQ:MASI - Free Report) by 5.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 747,498 shares of the medical equipment provider's stock after selling 45,437 shares during the quarter. Masimo accounts for about 1.9% of Liontrust Investment Partners LLP's portfolio, making the stock its 15th largest position. Liontrust Investment Partners LLP owned approximately 1.38% of Masimo worth $124,533,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Xponance Inc. lifted its holdings in shares of Masimo by 1.1% during the 1st quarter. Xponance Inc. now owns 7,101 shares of the medical equipment provider's stock valued at $1,183,000 after purchasing an additional 76 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Masimo by 1.5% during the 1st quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider's stock valued at $1,051,000 after purchasing an additional 92 shares in the last quarter. State of Michigan Retirement System lifted its holdings in shares of Masimo by 1.0% during the 1st quarter. State of Michigan Retirement System now owns 10,596 shares of the medical equipment provider's stock valued at $1,765,000 after purchasing an additional 100 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Masimo by 0.8% during the 1st quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the medical equipment provider's stock valued at $2,066,000 after purchasing an additional 100 shares in the last quarter. Finally, Securian Asset Management Inc. lifted its holdings in shares of Masimo by 3.0% during the 1st quarter. Securian Asset Management Inc. now owns 3,433 shares of the medical equipment provider's stock valued at $572,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Analyst Ratings Changes

MASI has been the topic of several recent analyst reports. Wells Fargo & Company cut their price objective on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Wall Street Zen cut Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Raymond James Financial cut their price objective on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Piper Sandler lifted their target price on Masimo from $200.00 to $210.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Finally, BTIG Research reissued a "buy" rating on shares of Masimo in a research report on Thursday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $193.60.

Insider Buying and Selling at Masimo

In related news, Director William R. Jellison purchased 3,000 shares of the stock in a transaction on Monday, August 11th. The shares were purchased at an average price of $145.98 per share, with a total value of $437,940.00. Following the transaction, the director directly owned 4,790 shares of the company's stock, valued at $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 16.90% of the stock is owned by company insiders.

Masimo Stock Up 0.0%

Masimo stock traded up $0.06 during midday trading on Monday, reaching $153.93. The stock had a trading volume of 528,907 shares, compared to its average volume of 855,003. The firm's fifty day simple moving average is $160.72 and its 200-day simple moving average is $163.60. Masimo Corporation has a 1-year low of $107.98 and a 1-year high of $194.88. The stock has a market capitalization of $8.36 billion, a P/E ratio of -18.07 and a beta of 1.21. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.11. The business had revenue of $370.90 million for the quarter, compared to analyst estimates of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%. Masimo's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.86 EPS. As a group, analysts expect that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.